JPMorgan on Apellis Pharmaceuticals (APLS): 'Recall The FAERS Database Is NOT Adjudicated, And It Is Dangerous To Over Interpret'
Tweet Send to a Friend
(Updated - April 30, 2024 12:35 PM EDT)
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $79.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $79.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
